Peer-reviewed veterinary case report
15-week CHOP chemo for dogs with multicentric lymphoma results
By Burton, J H et al.·Published in Veterinary and comparative oncology·2013·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
- Species:
- dog
Plain-English summary
A group of 31 dogs with multicentric lymphoma (a type of cancer affecting lymph nodes) were treated with a 15-week chemotherapy plan called CHOP. Remarkably, all the dogs responded to the treatment, with an average time before the cancer worsened being about 140 days. Interestingly, dogs that had to pause treatment due to side effects ended up living longer than those who didn't experience any issues. This suggests that adjusting the dose based on each dog's tolerance could be important for their recovery.
People also search for: dog lymphoma treatment options · CHOP chemotherapy for dogs · canine cancer survival rates
Abstract
Dose intense CHOP protocols have been shown to improve outcome for people with non-Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Thirty-one client owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression-free interval (PFI) of 140 days [95% confidence interval (CI) 91-335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22548975/